AstraZeneca to Acquire TeneoTwo for ~$1.27B

Share this
AstraZeneca to Acquire TeneoTwo for ~$1.27B

AstraZeneca to Acquire TeneoTwo for ~$1.27B


  • AstraZeneca to acquire all outstanding equity of TeneoTwo in exchange for $100M up front. TeneoTwo’s equity holders to receive ~$805M in R&D-related milestones, and ~$360M in commercial-related milestones. The transaction is expected to close in Q3’22
  • The acquisition will advance the development of TNB-486 (bispecific CD19 & CD3 T-cell engager, currently in P-I study) for B-cell hematologic malignancies. TNB-486 broadens AstraZeneca's hematology pipeline & includes multiple therapy modalities & mechanisms to target blood cancer that builds on the success of Calquence
  • TNB-486 as monothx. or in combination with CD20-targeted therapy can deepen clinical responses & enhance patient outcomes by refocusing the body's natural immune response to target B-cell malignancies

Ref: AstraZeneca | Image: AstraZeneca

Click here to­ read the full press release 


Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions